Tickers

1. Composite Trajectory Verdict

The income statement matters most for assessing STAA because its high-gross-margin, high-operating-leverage model makes profitability trends the clearest indicator of whether the China-driven volume recovery is translating into sustainable earnings.

Composite Trajectory: Mixed

Annual results show a sharp deterioration: FY2025 net sales fell 23.7% to $239.4M, operating income swung to a -$91.7M loss from -$12.6M in FY2024, and operating cash flow turned negative at -$34.2M (10-K FY2025, MD&A Net Sales table; 10-K FY2025, Consolidated Statements of Operations; 10-K FY2025, Cash flows summary). In contrast, the most recent quarterly periods show dramatic year-over-year improvement: six-month net sales surged 115.2% to $187.1M, operating income reached +$18.1M vs -$87.4M, and net income was +$13.3M vs -$71.0M (10-Q Q2 FY2026, Condensed Statements of Operations). Cash generation remains negative but less so (-$2.0M vs -$33.0M), and the balance sheet shows modest quarterly improvement in equity and working capital despite a slight cash decline. The annual and quarterly trends point in opposite directions, yielding a mixed composite picture.

2. Red Flags

• Operating cash flow vs. earnings divergence: H1 FY2026 net income was +$13.3M but operating cash flow was -$2.0M, driven by a $49.2M increase in accounts receivable (10-Q Q2 FY2026, Condensed Statements of Cash Flows).
• Elevated inventory levels: Days’ Inventory on Hand (DOH) was 219 days at FY2025 end, down from 367 days in FY2024 but still high, with finished goods including $4.4M of consignment inventory at July 3, 2026 (10-K FY2025, Liquidity; 10-Q Q2 FY2026, Note 3).
• Customer concentration in receivables: China distributors accounted for 65% of trade receivables at July 3, 2026, up from 33% at January 2, 2026 (10-Q Q2 FY2026, Note 14).
• Recurring “non-recurring” charges: Merger costs of $17.1M in FY2025 and $6.7M in Q1 FY2026; restructuring charges of $28.6M in FY2025, $22.7M in Q1 FY2025, and $5.2M in Q2 FY2025 (10-K FY2025, MD&A; 10-Q Q1 FY2026, MD&A; 10-Q Q2 FY2026, Note 1).
• Gross margin pressure from dual manufacturing and tariffs: Management cites higher per-unit costs from low Swiss utilization and tariff exposure on U.S.-made lenses sold to China until Swiss supply reaches 100% by end of FY2026 (10-K FY2025, MD&A; 10-Q Q2 FY2026, MD&A).
• Volatile effective tax rates: FY2025 2.2%, FY2024 -123.2%, FY2023 36.6% (10-K FY2025, MD&A Provision for Income Taxes table).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results deteriorated sharply over three years: net sales dropped from $322.4M (FY2023) to $313.9M (FY2024) to $239.4M (FY2025); operating income fell from +$28.1M to -$12.6M to -$91.7M; net income from +$21.3M to -$20.2M to -$80.4M (10-K FY2025, Consolidated Statements of Operations). However, the two most recent comparable quarters show strong YoY improvement: Q1 FY2026 net sales $93.5M vs $42.6M, operating income +$8.0M vs -$57.3M; Q2 FY2026 net sales $93.5M vs $44.3M, operating income +$10.1M vs -$30.0M; six-month net sales $187.1M vs $86.9M, operating income +$18.1M vs -$87.4M (10-Q Q1 FY2026, MD&A Net Sales and Results tables; 10-Q Q2 FY2026, Condensed Statements of Operations). Gross margin improved to 74.1% for H1 FY2026 from 70.0% in H1 FY2025 (10-Q Q2 FY2026, Condensed Statements of Operations). The annual and quarterly series contradict each other.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow declined from +$14.6M (FY2023) to +$15.7M (FY2024) to -$34.2M (FY2025) (10-K FY2025, Cash flows summary). The six-month comparable period improved: -$2.0M for H1 FY2026 vs -$33.0M for H1 FY2025, though still negative due to a $49.2M accounts receivable build (10-Q Q2 FY2026, Condensed Statements of Cash Flows). Investing cash flow swung from -$59.2M (FY2024) to +$46.3M (FY2025) on investment maturities, then to +$0.8M in H1 FY2026 (10-K FY2025, Cash flows summary; 10-Q Q2 FY2026, Condensed Statements of Cash Flows). Financing cash flow was -$4.6M (FY2025) and -$3.2M (H1 FY2026), driven by tax-withholding repurchases (10-K FY2025, Cash flows summary; 10-Q Q2 FY2026, Condensed Statements of Cash Flows). The annual trend is negative; the recent six-month trend is less negative but not yet positive.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Annual position weakened: cash and investments fell from $232.4M (FY2023) to $230.5M (FY2024) to $187.5M (FY2025); working capital from $300.2M to $297.6M to $243.0M; total equity from $397.3M to $344.2M (10-K FY2025, Liquidity table; 10-K FY2025, Consolidated Balance Sheets). Since FY2025 end, the quarterly comparison shows modest improvement: cash and investments $181.5M at July 3, 2026 vs $187.5M at Jan 2, 2026; working capital $269.0M vs $243.0M; total equity $365.4M vs $344.2M (10-Q Q2 FY2026, Condensed Balance Sheets; 10-Q Q2 FY2026, Liquidity table). Inventories decreased to $46.8M from $55.5M, while accounts receivable nearly doubled to $98.5M from $50.1M (10-Q Q2 FY2026, Condensed Balance Sheets). Leverage remains low (no debt), but lease obligations total $35.9M (10-Q Q2 FY2026, Note 8).

6. Data Gaps

• Quarterly cash flow statements for individual quarters (only six-month aggregates provided in 10-Q July 2026; 10-Q April 2026 cash flow not included in provided filings).
• Full quarterly income statements for Q3 and Q4 FY2025 (only Q1 and Q2 FY2025 available via comparatives in 10-Qs).
• Annual FY2026 results (not yet filed).
• Detailed breakdown of “Other current liabilities” ($37.5M at July 3, 2026) and “Other non-current liabilities” (10-Q Q2 FY2026, Condensed Balance Sheets; 10-K FY2025, Consolidated Balance Sheets).
• Geographic disaggregation of operating expenses and capital expenditures beyond sales (10-K FY2025, Segment Reporting; 10-Q Q2 FY2026, Note 14).